NRC director granted 8,819 stock options
National Research Corp director Stephen H. Lockhart reported receiving a grant of director stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
National Research Corp director Stephen H. Lockhart reported receiving a grant of director stock options. On 01/22/2026, he was awarded 8,819 stock options with an exercise price of $22.01 per share under the company’s 2025 Omnibus Incentive Plan.
The options became exercisable on 01/22/2026 and expire on 01/22/2036. The grant was made as compensation for his participation in two in-person board meetings held after the 2025 Annual Meeting of Stockholders.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 8,819 | $0.00 | $0.00 |
Footnotes (1)
- F1. This award is a grant to the reporting person made under the Issuer's 2025 Omnibus Incentive Plan for participating in two in-person meetings since the 2025 Annual Meeting of Stockholders.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did NRC director Stephen H. Lockhart report on this Form 4?
What are the key terms of Stephen H. Lockhart’s NRC stock option grant?
Why did National Research Corp grant 8,819 options to director Stephen H. Lockhart?
How many NRC derivative securities does Stephen H. Lockhart own after this transaction?
Is Stephen H. Lockhart’s NRC stock option grant a direct or indirect holding?
AI-generated analysis. How Rhea-AI works. Not financial advice.